Diane M. Retallack, The Dow Chemical Company, 5501 Oberlin Dr, San Diego, CA 92121
The Pfenex Expression Technology™ platform, a robust Pseudomonas fluorescens-based system for the expression of recombinant proteins has been developed for the expression of therapeutic proteins, antibody derivatives and vaccines. Multiple factors can affect protein product yield and quality, for example: protease degradation, protein folding/inclusion body formation, efficient secretion, and correct disulfide bond formation. Pfenex Expression Technology™ offers solutions to overcome all of these bottlenecks to development on a single platform and has evolved strain development from a slow, iterative and inefficient process into a rapid, parallel, seamless and highly efficient one. We have assembled approximately 100 host strains that enable proper protein folding, support secretion to the periplasmic and extracellular spaces, and/or enhance proper disulfide bond formation. These, together a family of more than 80 expression plasmids containing a variety of transcription and translation regulators as well as a collection of periplasmic secretion signals, enable construction of thousands of strain and expression plasmid combinations to be screened in parallel. High throughput (HTP) methods are especially effective with this system allowing rapid identification of optimal expression plasmid/host strain combinations that will serve as production strains. Case studies will be presented which demonstrate rapid identification of optimal expression strategies that enable high yield of active protein in a scalable process. The combinations of technologies available with the Pfenex Expression Technology™ system make it operationally the most complete, flexible and productive discovery and development platform available today.